Science Explorer Back to mapMap
Institution · Compass Oncology

Most cited papers from Compass Oncology

What are the most cited papers from Compass Oncology?

The most cited paper from Compass Oncology is "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial" (Louis Fehrenbacher, Alexander I. Spira, Marcus D. Ballinger et al., 2016), with 2,823 citations. Next come "Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA" (1,567) and "Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set" (1,027).

Showing 50 of 60 papers. Every paper with more than 23 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial Louis Fehrenbacher, Alexander I. Spira, Marcus D. Ballinger et al. · The Lancet 9 Mar 2016 2,823
2 Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA M.C. Liu et al. · Annals of Oncology Open access159 authors 30 Mar 2020 1,567
3 Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set Eric A. Klein, Donald Richards, Allen Lee Cohn et al. · Annals of Oncology Open access 24 Jun 2021 1,027
4 Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Blood Open access 4 Mar 2014 646
5 Boundary spanning at the science–policy interface: the practitioners’ perspectives ANGELA T. BEDNAREK, Carina A. Wyborn, Christopher Cvitanovic et al. · Sustainability Science Open access 27 Mar 2018 342
6 Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS) Franck Morschhauser et al. · The Lancet Haematology Open access 29 Mar 2019 251
7 An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia Jeff Porter Sharman, Michael Hawkins, Kathryn S. Kolibaba et al. · Blood Open access 19 Feb 2015 186
8 Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma Nathan Hale Fowler et al. · Journal of Clinical Oncology Open access 8 Mar 2021 163
9 FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer Mafalda Oliveira, Cristina Saura, Paolo Giovanni Nuciforo et al. · Annals of Oncology Open access 25 May 2019 157
10 Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial Lee Steven Schwartzberg, Manuel Modiano, Bernardo Leon Rapoport et al. · The Lancet Oncology 10 Aug 2015 154
11 Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial Tomoko Yamazaki et al. · The Lancet Oncology 8 Aug 2022 147
12 Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials Bernardo Leon Rapoport, Martin Robert Chasen, Cesare Gridelli et al. · The Lancet Oncology 10 Aug 2015 142
13 Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study Hervé Tilly, Franck Morschhauser, Nancy L. Bartlett et al. · The Lancet Oncology Open access 14 May 2019 140
14 Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study Marwan Fakih et al. · EClinicalMedicine Open access Apr 2023 114
15 Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study Nicholas J. Vogelzang et al. · Clinical Genitourinary Cancer Open access 16 May 2020 107
16 Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program Roxanne Payne, Lyn A. Glenn, Helena Maria Hoen et al. · Journal for ImmunoTherapy of Cancer Open access 2014 104
17 Prepectoral Revision Breast Reconstruction for Treatment of Implant-Associated Animation Deformity: A Review of 102 Reconstructions Allen Gabriel, Steven R. Sigalove, Noemi M. Sigalove et al. · Aesthetic Surgery Journal 20 Jan 2018 92
18 RO-ILS: Radiation Oncology Incident Learning System: A report from the first year of experience David J. Hoopes, Adam Paul Dicker, Nadine L. Eads et al. · Practical Radiation Oncology 25 Jun 2015 90
19 A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia Saroj Vadhan‐Raj, Rafat Abonour, Jonathan Wade Goldman et al. · Journal of Hematology & Oncology Open access 21 Mar 2017 89
20 Prepectoral Implant-Based Breast Reconstruction and Postmastectomy Radiotherapy: Short-Term Outcomes Steven R. Sigalove, G. Patrick Maxwell, Noemi M. Sigalove et al. · Plastic & Reconstructive Surgery Global Open Open access Dec 2017 82
21 A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer Antonio Jimeno, Julie E. Bauman, Charles Weissman et al. · Oral Oncology Open access 13 Jan 2015 79
22 Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia Kim-Hien T. Dao, Magdolna Solti, Julia E. Maxson et al. · Leukemia Research Reports Open access 2014 76
23 Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial Heinz‐Josef Lenz, Aparna R. Parikh, David Robert Spigel et al. · Journal for ImmunoTherapy of Cancer Open access Mar 2024 74
24 Efficacy of the neurokinin‐1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin‐based chemotherapy Paul Joseph Hesketh, Ian D. Schnadig, Lee Steven Schwartzberg et al. · Cancer Open access 13 May 2016 71
25 Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy David A. B. Smith, Paul Conkling, Donald Richards et al. · Cancer Immunology Immunotherapy Open access 26 Apr 2014 69
26 The Impact of Closed Incision Negative Pressure Therapy on Postoperative Breast Reconstruction Outcomes Allen Gabriel, Steven R. Sigalove, Noemi M. Sigalove et al. · Plastic & Reconstructive Surgery Global Open Open access Aug 2018 67
27 Impact of whole systems traditional Chinese medicine on in-vitro fertilization outcomes Lee Hullender Rubin, Michael S. Opsahl, Klaus E. Wiemer et al. · Reproductive BioMedicine Online Open access 24 Feb 2015 66
28 Ublituximab ( TG ‐1101), a novel glycoengineered anti‐ CD 20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial Jeff Porter Sharman, Charles Michael Farber, Daruka Mahadevan et al. · British Journal of Haematology Open access 16 Dec 2016 62
29 Recruitment and Retention of Families in Clinical Trials with Longitudinal Designs Sandra Adams Motzer, Jean Reynolds Moseley, Frances Marcus Lewis · Western Journal of Nursing Research Jun 1997 56
30 Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer Zhen Shi, Julia Dianne Wulfkuhle, Małgorzata Nowicka et al. · Clinical Cancer Research Open access 13 Dec 2021 55
31 Histologic and Clinical Changes in Vulvovaginal Tissue After Treatment With a Transcutaneous Temperature-Controlled Radiofrequency Device Monique J. Vanaman Wilson, Joanna Bolton, Isabela T. Jones et al. · Dermatologic Surgery 17 Jan 2018 55
32 Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study John G. Gribben et al. · Blood 5 Nov 2020 54
33 Robotic surgical staging for obese patients with endometrial cancer Karen Y. Tang, Stuart K. Gardiner, Claire H. Gould et al. · American Journal of Obstetrics and Gynecology 12 Jan 2012 52
34 Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial Jeff Porter Sharman, Danielle M. Brander, Anthony R. Mato et al. · The Lancet Haematology 23 Feb 2021 50
35 Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy Bernardo Leon Rapoport, Lee Steven Schwartzberg, Martin Robert Chasen et al. · European Journal of Cancer Open access 4 Feb 2016 48
36 Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices Guru Sonpavde, Menaka Bhor, Daniel Hennessy et al. · Clinical Genitourinary Cancer Open access 9 Jan 2015 48
37 An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma David Jacob Andorsky, Kathryn S. Kolibaba, Sarit E. Assouline et al. · British Journal of Haematology Open access 5 Sep 2018 47
38 Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward Abhenil Mittal, Myung Sun Kim, S. Terence Dunn et al. · EClinicalMedicine Open access 13 Sep 2024 46
39 Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: The circulating cell-free genome atlas (CCGA) study M.C. Liu, Eric A. Klein, Earl A. Hubbell et al. · Annals of Oncology Open access Oct 2018 46
40 Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study Jennifer Keating Litton, Joseph Thaddeus Beck, Jason Michael Jones et al. · The Oncologist Open access 15 Jun 2023 45
41 TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial Nikhil Chauhan, Mary F. Mulcahy, Riad Salem et al. · JMIR Research Protocols Open access 17 Jan 2019 44
42 The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma Shwetha H. Manjunath, Adam D. Cohen, Simon Francis Lacey et al. · Clinical Cancer Research Open access 15 Sep 2021 43
43 Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin Uma Borate, Amitkumar Mehta, Vishnu Reddy et al. · Leukemia Research Open access 28 Feb 2016 41
44 Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial Nikhil Chauhan, Janet Bukovcan, Éveline Boucher et al. · JMIR Research Protocols Open access 9 Jul 2018 40
45 Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918) John Paul Leonard, Kathryn S. Kolibaba, James Andrew Reeves et al. · Blood 3 Dec 2015 38
46 Psoriasiform eruptions during Kawasaki disease (KD): A distinct phenotype Ellen S. Haddock, Antoanella Calame, Chisato Shimizu et al. · Journal of the American Academy of Dermatology Open access 5 Mar 2016 35
47 Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study Joshua Jemison McFarlane, Mark D. Kochenderfer, Mark R. Olsen et al. · Clinical Genitourinary Cancer Open access 14 Jun 2020 33
48 Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma Eileen Mary O'Reilly, Diletta Barone, Devalingam Mahalingam et al. · European Journal of Cancer Open access 27 Apr 2020 33
49 Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: Is it necessary? Sarah E. Gill, Kari Savage, Weiya Zhang Wysham et al. · Gynecologic Oncology 21 Mar 2013 33
50 Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma Mustafa Khasraw, Michael Weller, David Lorente et al. · Neuro-Oncology Advances Open access 2021 29

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.